Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer / Michail Ignatiadis (u. a.) / Buch / Recent Results in Cancer Research / Englisch / 2012 / Springer-Verlag GmbH - copertina rigida, flessible

Libro nella banca dati dal 2007-07-25T05:23:28+02:00 (Rome)
Pagina di dettaglio ultima modifica in 2024-02-11T15:46:20+01:00 (Rome)
ISBN/EAN: 9783642281594

ISBN - Stili di scrittura alternativi:
3-642-28159-1, 978-3-642-28159-4
Stili di scrittura alternativi e concetti di ricerca simili:
Autore del libro : pant, pantel, michail, klaus christ, ign, christos, sotiriou peter nikolaus mina
Titolo del libro: cancer, tumors the breast, this serious one breast, mini, cel, residu, tum, min minim, minimal art, tumor, sang homericus

Dati dell'editore

Autore: Michail Ignatiadis; Christos Sotiriou; Klaus Pantel
Titolo: Recent Results in Cancer Research; Minimal Residual Disease and Circulating Tumor Cells in Breast Cancer
Editore: Springer; Springer Berlin
254 Pagine
Anno di pubblicazione: 2012-04-23
Berlin; Heidelberg; DE
Stampato / Fatto in
Lingua: Inglese
160,49 € (DE)
164,99 € (AT)
177,00 CHF (CH)
POD
XIV, 254 p.

BB; Hardcover, Softcover / Medizin/Klinische Fächer; Onkologie; Verstehen; Medizin, Gesundheit; Breast cancer; Circulating nucleic acids; Circulating tumor cells; Micrometastasis; Minimal residual disease; surgical oncology; Oncology; Gynecology; Cancer Therapy; Pathology; Cancer Biology; Gynäkologie und Geburtshilfe; Pathologie; BC

Minimal residual disease and circulating tumor cells in breast cancer: Open questions for research.- Minimal residual disease and breast cancer metastasis.- Self-seeding in cancer.- Microenvironments dictating tumor cell dormancy.- Technologies for circulating tumor cell (CTC) and disseminated tumor cell (DTC) detection and characterization.- Immunomagnetic separation technologies.- Microfluidic technologies for the isolation of CTCs.- EPISPOT assay: Detection of viable disseminating tumor cells in solid tumor patients.- Advances in optical technologies for rare cell detection and characterization.- Size-based enrichment technologies for circulating tumor cell (CTC) detection and characterization.- Emerging technologies for CTC detection based on depletion of normal cells.- Molecular assays for the detection and characterization of CTCs.- Multiplex molecular analysis of CTCs.- Other blood-based biomarkers.- Circulating DNA and next generation sequencing.- Circulating microRNAs as non-invasive biomarkers in breast cancer.- Circulating endothelial cells and circulating endothelial progenitors.- Disseminated tumor cells (DTCs) and circulating tumor cells (CTCs) in breast cancer clinical research and practice.- Bone marrow DTCs.- CTCs in primary breast cancer.- CTCs in early breast cancer.- CTCs in metastatic breast cancer.- HER2-positive DTCs/CTCs in breast cancer.- DTCs and CTCs in breast cancer – 5 decades later.- Drug and circulating tumor cell co-development.- Challenges in drug and biomarker co-development.- Challenges and opportunities in the use of CTCs for companion diagnostic development.

Most deaths from carcinomas are caused by the hematogenous dissemination of cancer cells to distant organs and the eventual development of metastases. When found in the bone marrow or peripheral blood of carcinoma patients, occult cancer cells are referred to as disseminated tumor cells (DTCs) or circulating tumor cells (CTCs). CTCs and DTCs are considered surrogates of minimal residual disease, i.e., the presence of malignant cells in distant organs that are undetectable by conventional imaging and laboratory tests used for tumor staging after curative surgery of the primary tumor.

In this book, leading investigators in the field provide up-to-date information on a series of important questions, including:

-  How can the study of minimal residual disease and CTCs help us to better understand breast cancer metastasis?

-  What technologies are available for the detection and characterization of CTCs and DTCs, and what are their relative merits?

-  How are DTCs and CTCs relevant to clinical research and practice?

- What is the role of other blood-based biomarkers such as circulating endothelial cells and circulating nucleic acids?

-  What are the challenges in drug and biomarker co-development and the use of CTCs for companion diagnostic development?

Provides up-to-date information on topical issues concerning minimal residual disease in breast cancer patients

Appraises the technologies available for detection and characterization of circulating and disseminated tumor cells (CTCs/DTCs)

Discusses the relevance of CTCs and DTCs in breast cancer clinical research and practice, and the role of other blood-based biomarkers